United States - English - NLM (National Library of Medicine)

hospira, inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - dextrose monohydrate 50 g in 1000 ml - these solutions are indicated in patients requiring parenteral administration of potassium chloride with minimal carbohydrate calories and sodium chloride. solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication - prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw needle after injecting medication. - the additive port may be protected by covering with an additive cap. - mix container contents thoroughly. preparation for admin

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7), dextrose monohydrate (unii: lx22yl083g) (dextrose - unii:iy9xdz35w2) - injection - 200 ug in 1 ml - milrinone lactate in 5% dextrose injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate in 5% dextrose injection is contraindicated in patients who are hypersensitive to milrinone. solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.

United States - English - NLM (National Library of Medicine)

agrilabs - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - for use as an aid in the treatment of acetonemia (ketosis) in cattle.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - water for injections, quantity: 1000 ml - injection, intravenous infusion - excipient ingredients: - water for injections bp is used to dissolve or dilute substances or preparations for parenteral administration. water for injections bp may also be used as an irrigating solution for small wounds or during minor surgical procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - water for injections, quantity: 500 ml - injection, intravenous infusion - excipient ingredients: - water for injections bp is used to dissolve or dilute substances or preparations for parenteral administration. water for injections bp may also be used as an irrigating solution for small wounds or during minor surgical procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - water for injections, quantity: 250 ml - injection, intravenous infusion - excipient ingredients: - water for injections bp is used to dissolve or dilute substances or preparations for parenteral administration. water for injections bp may also be used as an irrigating solution for small wounds or during minor surgical procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - water for injections, quantity: 100 ml - injection, intravenous infusion - excipient ingredients: - water for injections bp is used to dissolve or dilute substances or preparations for parenteral administration. water for injections bp may also be used as an irrigating solution for small wounds or during minor surgical procedures.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - water (unii: 059qf0ko0r) (water - unii:059qf0ko0r) - this parenteral preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered. sterile water for injection must be made approximately isotonic prior to use.

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - water (unii: 059qf0ko0r) (water - unii:059qf0ko0r) - this parenteral preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered. sterile water for injection, usp must be made approximately isotonic prior to use.

United States - English - NLM (National Library of Medicine)

fresenius medical care north america - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid - unii:33x04xa5at), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698) - delflex® is indicated in the treatment of chronic kidney failure in patients being maintained on peritoneal dialysis. none. risk summary delflex solutions consist of electrolytes, lactate, and bicarbonate at physiological levels, and glucose to facilitate ultrafiltration. while there are no adequate and well controlled studies in pregnant women, appropriate administration of delflex with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm. animal reproduction studies have not been conducted with delflex. the estimated background risk of major birth defects and miscarriage for the indicated population are unknown. all pregnancies have a background risk of birth defect, loss or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary the components of delflex solutions are excreted in human milk. appropriat